Enveric Biosciences, Inc.
ENVB
$5.90
$0.081.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.24M | 6.01M | 6.04M | 6.56M | 5.02M |
| Depreciation & Amortization | 243.90K | 288.30K | 333.10K | 337.50K | 339.70K |
| Other Operating Expenses | -246.10K | -246.10K | -246.10K | -246.10K | -107.20K |
| Total Operating Expenses | 9.75M | 9.96M | 9.34M | 9.63M | 8.84M |
| Operating Income | -9.75M | -9.96M | -9.34M | -9.63M | -8.84M |
| Income Before Tax | -9.73M | -9.94M | -9.30M | -9.57M | -9.83M |
| Income Tax Expenses | 7.20K | 7.20K | 7.20K | 8.90K | 24.00K |
| Earnings from Continuing Operations | -9.73 | -9.94 | -9.30 | -9.57 | -9.86 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.73M | -9.94M | -9.30M | -9.57M | -9.86M |
| EBIT | -9.75M | -9.96M | -9.34M | -9.63M | -8.84M |
| EBITDA | -9.51M | -9.68M | -9.01M | -9.29M | -8.50M |
| EPS Basic | -94.63 | -126.92 | -159.86 | -255.80 | -468.88 |
| Normalized Basic EPS | -56.04 | -79.24 | -99.83 | -159.74 | -291.90 |
| EPS Diluted | -94.63 | -126.92 | -159.86 | -255.80 | -468.88 |
| Normalized Diluted EPS | -56.04 | -79.24 | -99.83 | -159.74 | -291.90 |
| Average Basic Shares Outstanding | 734.10K | 469.30K | 295.20K | 167.60K | 125.50K |
| Average Diluted Shares Outstanding | 734.10K | 469.30K | 295.20K | 167.60K | 125.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |